EGA
ALT icon

Eagle Global Advisors’s Altimmune ALT Stock Holding History

Eagle Global Advisors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-296
Closed -$72K – 438
2017
Q1 		$72K Hold
296
– – ﹤0.01% 379
2016
Q4 		$289K Buy
+296
New +$265K 0.01% 277

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Eagle Global Advisors's ALT Position: Q2 2017 in Review

Eagle Global Advisors sold out of Altimmune (ALT) in Q2 2017, closing a stake of 296 shares — an estimated $72K sold.

Eagle Global Advisors first reported a position in ALT in Q4 2016 and held it in 2 quarters. The position peaked at $289K in Q4 2016. 41 funds tracked by Wall St. Rank hold ALT as of Q2 2017.

  • Eagle Global Advisors reported no remaining Altimmune position as of Q2 2017 after selling out during the quarter.
  • Eagle Global Advisors sold 296 Altimmune shares in Q2 2017, an estimated $72K.
  • Eagle Global Advisors first reported a position in Altimmune in Q4 2016 and held it in 2 quarters.
  • Eagle Global Advisors's Altimmune position peaked at $289K in Q4 2016.
  • 41 funds tracked by Wall St. Rank held Altimmune as of Q2 2017.

Based on Eagle Global Advisors's 13F filing for Q2 2017, filed 27 Jul 2017.